Cargando…

Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes

INTRODUCTION: Dapagliflozin is an orally administered selective sodium-glucose cotransporter 2 (SGLT2) inhibitor under development for the treatment of type 2 diabetes mellitus (T2DM). Dapagliflozin lowers blood glucose through a reduction in renal glucose reabsorption. This study was performed to a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imamura, Akira, Kusunoki, Masahito, Ueda, Shinya, Hayashi, Nobuya, Imai, Yasuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687097/ https://www.ncbi.nlm.nih.gov/pubmed/23307267 http://dx.doi.org/10.1007/s13300-012-0016-5

Ejemplares similares

Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes
por: Watada, Hirotaka, et al.
Publicado: (2018)

Pharmacokinetic study of metformin to compare a voglibose/metformin fixed-dose combination with coadministered voglibose and metformin
por: Choi, Hyang-Ki, et al.
Publicado: (2015)

Cost‐effectiveness analysis of voglibose for prevention of type 2 diabetes mellitus in Japanese patients with impaired glucose tolerance
por: Ikeda, Shunya, et al.
Publicado: (2010)

Alpha-Glucosidase Inhibitor Voglibose Suppresses Azoxymethane-Induced Colonic Preneoplastic Lesions in Diabetic and Obese Mice
por: Kato, Junichi, et al.
Publicado: (2020)

Sitagliptin added to voglibose monotherapy improves glycemic control in patients with type 2 diabetes
por: Tajima, Naoko, et al.
Publicado: (2013)

Urinary glucose excretion after dapagliflozin treatment: An exposure‐response modelling comparison between Japanese and non‐Japanese patients diagnosed with type 1 diabetes mellitus
por: Sokolov, Victor, et al.
Publicado: (2018)

Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus
por: Melin, Johanna, et al.
Publicado: (2022)

Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study
por: Iwamoto, Y, et al.
Publicado: (2010)

Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
por: Iijima, Hiroaki, et al.
Publicado: (2015)

Effects of combination therapy with mitiglinide and voglibose on postprandial plasma glucose in patients with type 2 diabetes mellitus
por: Konya, Hiroyuki, et al.
Publicado: (2013)

Role of Intestinal Microbiota in Metabolism of Voglibose In Vitro and In Vivo
por: Nepal, Mahesh Raj, et al.
Publicado: (2020)

Comparison of efficacy of concomitant administration of mitiglinide with voglibose and double dose of mitiglinide in patients with type 2 diabetes mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2010)

Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial
por: Oh, Tae Jung, et al.
Publicado: (2019)

Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes
por: Shi, Chunhong, et al.
Publicado: (2019)

Longitudinal impact of dapagliflozin treatment on ventricular repolarization heterogeneity in patients with type 2 diabetes
por: Sato, Tatsuya, et al.
Publicado: (2019)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

Effect of Astragali radix extract on pharmacokinetic behavior of dapagliflozin in healthy and type 2 diabetic rats
por: Du, Wandi, et al.
Publicado: (2023)

The effects of the voglibose on non-alcoholic fatty liver disease in mice model
por: Bae, Jaehyun, et al.
Publicado: (2022)

Dapagliflozin as Monotherapy or Combination Therapy in Japanese Patients with Type 2 Diabetes: an Open-Label Study
por: Kaku, Kohei, et al.
Publicado: (2014)

Comparison of effects of sitagliptin and voglibose on left ventricular diastolic dysfunction in patients with type 2 diabetes: results of the 3D trial
por: Oe, Hiroki, et al.
Publicado: (2015)

Effect of Linagliptin and Voglibose on metabolic profile in patients with Type 2 Diabetes: a randomized, double-blind, placebo-controlled trial
por: Parthan, Girish, et al.
Publicado: (2018)

Linagliptin monotherapy compared with voglibose monotherapy in patients with type 2 diabetes undergoing hemodialysis: a 12-week randomized trial
por: Mori, Katsuhito, et al.
Publicado: (2016)

Effects of luseogliflozin and voglibose on high-risk lipid profiles and inflammatory markers in diabetes patients with heart failure
por: Ejiri, Kentaro, et al.
Publicado: (2022)

Pharmacokinetic and Pharmacodynamic Profiles of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus and Moderate Renal Impairment
por: Inagaki, Nobuya, et al.
Publicado: (2014)

Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
por: Kinguchi, Sho, et al.
Publicado: (2019)

Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose
por: Kasthuri, Selvam, et al.
Publicado: (2021)

Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo
por: Horie, Yoshiharu, et al.
Publicado: (2009)

Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment
por: van der Walt, J-S, et al.
Publicado: (2013)

Psychological Factors Motivating Male Japanese Workers With Type 2 Diabetes to Engage in Dietary Modifications: A Qualitative Descriptive Study
por: Morinishi, Kanako, et al.
Publicado: (2023)

Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus
por: Sugiyama, Seigo, et al.
Publicado: (2018)

Correction to: Dapagliflozin: A Review in Type 1 Diabetes
por: Paik, Julia, et al.
Publicado: (2019)

Correction to: Dapagliflozin: A Review in Type 2 Diabetes
por: Dhillon, Sohita
Publicado: (2019)

Dapagliflozin: an effective adjunctive treatment in type 1 diabetes
por: Yadegarfar, Ghasem, et al.
Publicado: (2021)

Nephroprotective Effects of Dapagliflozin in Patients with Type 2 Diabetes
por: Iijima, Yasuhiro, et al.
Publicado: (2023)

Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add‐on to metformin in patients with type 2 diabetes
por: Müller‐Wieland, Dirk, et al.
Publicado: (2018)

Evaluation of the Pharmacokinetics and Exposure–Response Relationship of Dapagliflozin in Patients without Diabetes and with Chronic Kidney Disease
por: van der Aart-van der Beek, Annemarie B., et al.
Publicado: (2021)

Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection
por: Osawa, Mayu, et al.
Publicado: (2018)

Case of pneumatosis cystoides intestinalis with intra‐abdominal free air developed during treatment with voglibose
por: Hisanaga, Etsuko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4uvcsp6524cn3ar2q2t5jjjtiq